Objective To observe the clinical curative effect of computer aided cognitive rehabilitation system for the treatment of cognitive impairment after stroke.Methods The data of 70 cases of cognitive impairment after stroke patients were randomly selected from November 2011-November 2012 in our hospital,according to the treatment method,patients were randomly divided into research group (n=35) and control group (n=35).The control group patients were given cognitive training,sports and drugs and other conventional treatment.On the basis of conventional treatment,the research group patients were given computer aided cognitive rehabilitation system treatment.Then we observed and compared the clinical curative effect of two groups of patients after treatment.Results The cognitive rating scale (LOTCA) scores in patients in the research group was better than that in the control group,the difference was statistically significant (P ＜ 0.05) The simple mental state examination (MMSE) score of patients in the research group was better than that in the control group,the difference was statistically significant (P ＜ 0.05).Conclusion Computer assisted cognitive rehabilitation system for patients with cognitive impairment after stroke has significant curative effect,and should be popularized and widely used in clinical treatment.

OBJECTIVEWolff-Parkinson-White syndrome (WPW) is considered to be an autosomal dominant hereditary disease, but the gene is not identified. The objective of this study was to localize the genetic loci of Wolff-Parkinson-White syndrome.

METHODSLinkage analysis between the disease of Wolff-Parkinson-White syndrome and 3 STR (short tandem repeats) markers on 7q3 (D7S505, D7S688, and D7S483) was tested in 3 kindreds of the Wolff-Parkinson-White syndrome (101 numbers in total) by genotyping.

RESULTSWolff-Parkinson-White syndrome was linked to the loci above. The maximum two-point Lod score detected at D7S505 was 6.4 at a recombination fraction (theta) of 0.1; the Lod score of D7S688, D7S483 was 5.3 vs 2.5.

CONCLUSIONThe gene of Wolff-Parkinson-White syndrome is located at 7q3.

Adolescent ; Adult ; Child ; Chromosome Mapping ; Chromosomes, Human, Pair 7 ; Female ; Genetic Markers ; Humans ; Male ; Middle Aged ; Tandem Repeat Sequences ; Wolff-Parkinson-White Syndrome ; genetics

Objective To observe the clinical efficacy of umbilical compress with anti-cancer Xiaogu formula in managing malignant ascites. Methods A total of 56 patients with malignant ascites who met the inclusion criteria were randomized into 28 patients in the treatment group and 28 patients in the control group. The control group was treated with one type of diuretic, and the treatment group was given umbilical compress using Anti-Cancer Xiaogu formula and diuretics. Both groups were treated for 14 days. The changes of abdominal girth, 24 h urine volume, ascites efficacy, TCM syndrome scores, quality of life and adverse reactions were observed. Results The decrease in the maximum depth difference of the ascites in the treatment group was significantly greater than that of the control group (1.16 ± 1.29 vs. 0.00 ± 1.34, Z=-2.553). The difference was statistically significant (P<0.05). The decrease in abdominal girth in the treatment group was significantly larger than that in the control group (0.57 ± 0.55 vs. 2.61 ± 0.28, Z=-2.264). The difference was statistically significant (P<0.05). The in 24-hour urine volume in the treatment group after intervention (-800.18 ± 64.12 vs.-683.57 ± 55.38, Z=-1.770) was no statistically significant (P>0.05). The response rate in the treatment group was 92.9％ (26/28), while that of the control group was 89.3％ (25/28).treatment group was 71.4％, while that of the control group was 35.7％. The difference was statistically significant (P<0.05). The increase in KPS in the treatment group was significantly higher than that of the control group. The difference was statistically significant (P<0.05). Conclusions Anti-cancer Xiaogu umbilical cord combined with diuretic can reduce the degree of malignant ascites, alleviate clinical symptoms, improve quality of life and decrease the occurrence of adverse reactions when used concomitantly with diuretics in the management of malignant ascites.